Their device replaces regurgitating mitral and tricuspid valves using a transfemoral-transseptal approach, offering benefits such as minimal protrusion to the left ventricle and increased safety. The company is currently evaluating the safety and performance of its system in clinical studies and aims to seek approvals in the EU, China, and North America. Cardiovalve is part of Venus Medtech and aims to provide innovative solutions for heart valve disease patients without the need for open-heart surgery.